Researchers review the future of schizophrenia treatment, highlighting TAAR1 agonists, NMDA enhancers, and the gut-brain axis ...

Scientists at the Broad Institute say they're finally cracking open the root causes of schizophrenia. Until now, the biology behind the disease has been hard to pin down. Earlier research had shown ...

Although the causes of schizophrenia are not well understood, health professionals in recent decades have been increasingly intrigued by the links between this complicated illness and human physical ...

Recent advances in neuroscience have increasingly implicated oxidative stress in the pathophysiology of schizophrenia. Oxidative stress arises from an imbalance between the production of reactive ...

Schizophrenia is a disorder with readily observable symptoms including hallucinations, delusions, social withdrawal, apathy, and disorganized thinking and behavior. It is also associated with ...

For decades, schizophrenia and bipolar disorder (BD) were treated as distinct and unrelated psychiatric disorders. Schizophrenia is a psychiatric disorder characterized by altered thinking and ...

Xanomeline-trospium (KarXT) — a novel therapy that combines a muscarinic receptor agonist with an anticholinergic agent — led to statistically significant and clinically meaningful improvements in ...

Daybue was turned down for Rett syndrome, and Iloperidone for schizophrenia and bipolar I, with safety and benefit-risk concerns cited in both cases.